BRPI1014821A2 - "inibidores de replicação de hiv" - Google Patents

"inibidores de replicação de hiv"

Info

Publication number
BRPI1014821A2
BRPI1014821A2 BRPI1014821A BRPI1014821A BRPI1014821A2 BR PI1014821 A2 BRPI1014821 A2 BR PI1014821A2 BR PI1014821 A BRPI1014821 A BR PI1014821A BR PI1014821 A BRPI1014821 A BR PI1014821A BR PI1014821 A2 BRPI1014821 A2 BR PI1014821A2
Authority
BR
Brazil
Prior art keywords
hiv replication
replication inhibitors
inhibitors
hiv
replication
Prior art date
Application number
BRPI1014821A
Other languages
English (en)
Inventor
Anne-Marie Faucher
Christiane Yoakim
Claudio Sturino
Clint James
Eric Malenfant
Jean-Eric Lacoste
Joannie Minville
Louis Morency
Martin Duplessis
Martin Tremblay
Patrick Deroy
Paul J Edwards
Sebastien Morin
Teddy Halmos
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI1014821A2 publication Critical patent/BRPI1014821A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1014821A 2009-04-09 2010-04-07 "inibidores de replicação de hiv" BRPI1014821A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16803209P 2009-04-09 2009-04-09
US26368909P 2009-11-23 2009-11-23
PCT/CA2010/000478 WO2010115264A1 (en) 2009-04-09 2010-04-07 Inhibitors of hiv replication

Publications (1)

Publication Number Publication Date
BRPI1014821A2 true BRPI1014821A2 (pt) 2016-04-05

Family

ID=42934876

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014821A BRPI1014821A2 (pt) 2009-04-09 2010-04-07 "inibidores de replicação de hiv"

Country Status (15)

Country Link
US (1) US8349839B2 (pt)
EP (1) EP2417140B1 (pt)
JP (1) JP5643290B2 (pt)
KR (1) KR20120034592A (pt)
CN (1) CN102388051A (pt)
AR (1) AR076252A1 (pt)
AU (1) AU2010234241A1 (pt)
BR (1) BRPI1014821A2 (pt)
CA (1) CA2758149A1 (pt)
CL (1) CL2011002258A1 (pt)
EA (1) EA201101397A1 (pt)
IL (1) IL214606A0 (pt)
MX (1) MX2011010582A (pt)
TW (1) TW201103940A (pt)
WO (1) WO2010115264A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6144698B2 (ja) * 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hiv複製の阻害剤としての縮合三環式化合物
EP3233797B1 (en) * 2015-01-18 2019-05-08 SRI International Inc. Map4k4 (hgk) inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
TW201629026A (zh) 2015-02-02 2016-08-16 佛瑪治療公司 作為hdac抑制劑的3-烷基雙環[4,5,0]異羥肟酸
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020028482A1 (en) * 2018-07-31 2020-02-06 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN111560022A (zh) * 2020-05-13 2020-08-21 深圳职业技术学院 四氢苯并呋喃[3,2-d]嘧啶类衍生物及其制备方法及应用
CN116332947A (zh) * 2021-12-24 2023-06-27 上海海和药物研究开发股份有限公司 具有mat2a抑制活性的嘧啶-2(1h)-酮并二环类化合物及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8016A (en) * 1851-04-01 Improvement in the manufacture of india-rubber
JPH06172365A (ja) * 1992-12-11 1994-06-21 Yamasa Shoyu Co Ltd 10−チアイソアロキサジン誘導体およびその用途
JPH06220059A (ja) * 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
US6593337B1 (en) * 1999-10-19 2003-07-15 Bristol-Myers Squibb Pharma Company Tricyclic compounds useful as HIV reverse transcriptase inhibitors
EP1209158A1 (en) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substituted beta-carbolines
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
EP1559720A1 (en) 2002-11-08 2005-08-03 Kaneka Corporation Method of separating ergosterol
MXPA05005146A (es) 2002-11-15 2005-07-22 Tibotec Pharm Ltd Indolpiridinio sustituido como compuestos antiinfecciosos.
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
CN1812992A (zh) * 2003-04-28 2006-08-02 泰博特克药品有限公司 Hiv整合酶抑制剂
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
CN1870896A (zh) * 2003-10-20 2006-11-29 默克公司 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
CA2555132A1 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
KR20070015608A (ko) 2004-05-17 2007-02-05 티보텍 파마슈티칼즈 리미티드 1-헤테로사이클일-1,5-디히드로-피리도[3,2-b]인돌-2-온
MXPA06013312A (es) 2004-05-17 2007-02-02 Tibotec Pharm Ltd 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas 5-sustituidas y analogos como antivirales.
TW200607502A (en) 2004-05-17 2006-03-01 Tibotec Pharm Ltd 6, 7, 8, 9-substituted 1-phenyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones
MXPA06013315A (es) * 2004-05-17 2007-02-02 Tibotec Pharm Ltd 1,5-dihidro-pirido[3,2-b]indol-2-onas 4-sustituidas.
EA200602136A1 (ru) * 2004-05-17 2007-04-27 Тиботек Фармасьютикалз Лтд. Комбинации замещенных 1-фенил-1,5-дигидропиридо[3,2-b] индол-2-онов и других ингибиторов вич
ATE455777T1 (de) * 2004-07-23 2010-02-15 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
WO2006034583A1 (en) 2004-09-30 2006-04-06 Boehringer Ingelheim International Gmbh & Co Kg Alkynyl based dervatives of benzophenone as non-nucleoside reverse transcriptase inhibitors
EP1802299A2 (en) 2004-10-13 2007-07-04 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
US20060276440A1 (en) 2005-01-03 2006-12-07 An Wenqian F Treatment of inflammatory disorders
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
JP2009525310A (ja) 2006-02-03 2009-07-09 テイボテク・フアーマシユーチカルズ・リミテツド 突然変異したhivを処置する方法
WO2008037783A1 (en) 2006-09-29 2008-04-03 Tibotec Pharmaceuticals Ltd. Process for preparing 2-oxo-2,5-dihydro-1h-pyrido[3,2-b]indole-3-carbonitriles
DE102006062203A1 (de) * 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
JP2010519186A (ja) 2007-02-19 2010-06-03 スミスクライン ビーチャム コーポレーション 免疫調節物質としてのプリン誘導体
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors

Also Published As

Publication number Publication date
AR076252A1 (es) 2011-05-26
US20100261714A1 (en) 2010-10-14
EP2417140A4 (en) 2013-02-20
CA2758149A1 (en) 2010-10-14
JP2012523380A (ja) 2012-10-04
TW201103940A (en) 2011-02-01
MX2011010582A (es) 2011-10-19
CL2011002258A1 (es) 2012-02-10
WO2010115264A1 (en) 2010-10-14
EP2417140A1 (en) 2012-02-15
IL214606A0 (en) 2011-09-27
EP2417140B1 (en) 2014-11-26
AU2010234241A1 (en) 2011-09-08
US8349839B2 (en) 2013-01-08
KR20120034592A (ko) 2012-04-12
CN102388051A (zh) 2012-03-21
JP5643290B2 (ja) 2014-12-17
EA201101397A1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
CY2021008I2 (el) Πυριμιδινες οι οποιες παρεμποδιζουν την ανατυπωση ηιv
CY2018030I1 (el) Φαρμακοτεχνικη μορφη 514
BRPI0910307A2 (pt) inibidores de hiv integrase
FR16C1026I2 (fr) Inhibiteurs de la replication du virus de l'hepatite c
BR112012012872A2 (pt) "pirrolindinas de espiroindolinona"
BR112012014254A2 (pt) "artigo de múltiplas camadas"
CR10693A (es) Enantiomerically pure phosphoindoles as hiv inhibitors
BRPI1009315A2 (pt) agentes anti-inflamatórios
BRPI1012004A2 (pt) "forma farmacêutica"
EP2263545A4 (en) sonographer
BRPI1014956A2 (pt) agentes antinflamatórios.
BR112012003780A2 (pt) pregão semântico
EP2414948A4 (en) APPLICATION SHARING
BRPI0920521A2 (pt) combinação farmacêutica
DK3097925T3 (da) Farmaceutisk sammensætning
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
BRPI1004940A2 (pt) composição farmacêutica
BR112012004593A2 (pt) "método"
BR112012010595A2 (pt) "dispensdor"
BRPI1015939A2 (pt) composição farmacêutica
EP2099789A4 (en) INHIBITORS OF HIV REPLICATION
EP2189118A4 (en) ULTRASOUND DEVICE
FR2944062B1 (fr) Injecteur d'ergols
IL214606A0 (en) Inhibitors of hiv replication
BR112012003149A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]